Xuezhi Hao

机构：Northeast Agricultural University · ORCID：0000-0002-2846-2501

发表论文 35 篇 · 总被引 106 次 · h-index 6

代表论文

• MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling (2022 · Clinical & Translational Oncology · 被引 9)
• First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 7)
• The clinical significance of RET gene fusion among Chinese patients with lung cancer (2020 · Translational Cancer Research · 被引 6)
• Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer (2025 · Cancer Immunology Immunotherapy · 被引 4)
• Effectiveness of icotinib against non–small-cell lung cancer with uncommon EGFR mutations. (2018 · Journal of Clinical Oncology · 被引 3)
• Efficacy and safety of apatinib in extensive stage small cell lung cancer patients failed from two or more lines of chemotherapy. (2019 · Journal of Clinical Oncology · 被引 2)